Market revenue in 2023 | USD 10,489.3 million |
Market revenue in 2030 | USD 20,415.3 million |
Growth rate | 10% (CAGR from 2023 to 2030) |
Largest segment | Transdermal patches |
Fastest growing segment | Drug Eluting Stents |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Photodynamic Therapy Devices, Transdermal Patches, Wound Care Products, Infusion Pumps, Orthopedic Combination Products, Drug Eluting Stents, Inhalers, Antimicrobial Catheters |
Key market players worldwide | Abbott Laboratories, Terumo Corp, Stryker Corp, Viatris Inc, Medtronic PLC, Boston Scientific Corp, Novartis AG ADR, Becton Dickinson & Co, Teleflex Inc, W L Gore & Associates |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug device combination products market will help companies and investors design strategic landscapes.
Transdermal patches was the largest segment with a revenue share of 23.25% in 2023. Horizon Databook has segmented the Canada drug device combination products market based on photodynamic therapy devices, transdermal patches, wound care products, infusion pumps, orthopedic combination products, drug eluting stents, inhalers, antimicrobial catheters covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of developed healthcare infrastructure, increasing number of surgical procedures, rising number of healthcare centers, and launch of new products are some of the key factors driving market growth. Furthermore, Canadian Medicare is designed to ensure that all residents have easy access to physicians and hospital services, which is expected to boost the adoption of medical services, such as surgeries related to heart failure.
Furthermore, the rising prevalence of chronic diseases across Canada, such as Chronic Obstructive Pulmonary Disease (COPD) and pneumonia, is anticipated to drive market growth. According to the National Center for Biotechnology Information (NCBI), in 2021, the prevalence of COPD in Canada was 16.2% by fixed ratio and 11.2% by lower limits of normal. According to the Canadian Cancer Society, in 2020, about 115,800 Canadian men and around 110,000 Canadian women were diagnosed with cancer in Canada.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada drug device combination products market , including forecasts for subscribers. This country databook contains high-level insights into Canada drug device combination products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account